SciSparc Subsidiary Nears Major Acquisition Close with Conditional Regulatory Approval
SPRC sits 52% above its 52-week low of $2.98.
Summary
SciSparc's subsidiary, NeuroThera Labs, has received conditional regulatory approval for its acquisition of CliniQuantum. This marks a significant step towards completing the deal, which was initially announced in March 2026. The acquisition involves NeuroThera Labs taking a 54% stake in CliniQuantum for approximately $9.46 million, as detailed in a March 12, 2026 6-K filing. For a company of SciSparc's size, progressing with this material acquisition is a positive development, especially following recent concerns about its financial viability and Nasdaq compliance.
At the time of this announcement, SPRC was trading at $4.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $2.98 to $80.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.